Evaluation of eribulin and bevacizumab for the real world treatment of recurrent breast cancer

被引：0
|
作者：
Earashi, M. [1 ]
Matsui, K. [2 ]
Maeda, K. [2 ]
Fukushima, W. [3 ]
Shimada, K. [4 ]
Shimizu, T. [5 ]
Nozaki, Z. [6 ]
Tanada, Y. [6 ]
Oyama, K. [7 ]
Nagata, T. [8 ]
Tsuneda, A. [9 ]
Yoshikawa, A. [10 ]
Yoshida, T. [11 ]
Kiyohara, K. [12 ]
Iwata, K. [13 ]
Ii, T. [14 ]
机构：
[1] Yatsuo Gen Hosp, Dept Breast Suegery, Toyama, Japan
[2] Toyama Prefectural Cent Hosp, Depertment Surg, Toyama, Japan
[3] Takaoka City Hosp, Derartment Surg, Takaoka, Toyama, Japan
[4] Imizu Municipal Hosp, Dept Surg, Imizu, Toyama, Japan
[5] Saiseikai Toyama Hosp, Dept Surg, Toyama, Japan
[6] Toyama Red Cross Hosp, Dept Surg, Toyama, Japan
[7] Kouseiren Takaoka Hosp, Dept Surg, Takaoka, Toyama, Japan
[8] Toyama Univ Hosp, Dept Surg, Toyama, Japan
[9] Toyama Rosai Hosp, Dept Surg, Uozu, Toyama, Japan
[10] Toyama City Hosp, Dept Surg, Toyama, Japan
[11] Saiseikai Takaoka Hosp, Dept Surg, Takaoka, Toyama, Japan
[12] Tonami Gen Hosp, Dept Surg, Tonami, Toyama, Japan
[13] Kurobe City Hosp, Dept Surg, Kurobe, Japan
[14] Kouseiren Namerikawa Hosp, Dept Surg, Namerikawa, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
110P
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [1] Real-world effect of bevacizumab and eribulin on metastatic breast cancer using a propensity score matching analysis
    Matsui, Koshi
    Earashi, Mitsuharu
    Yoshikawa, Akemi
    Fukushima, Wataru
    Nozaki, Zensei
    Oyama, Kaeko
    Maeda, Kiichi
    Nakakura, Akiyoshi
    Morita, Satoshi
    Fujii, Tsutomu
    MOLECULAR AND CLINICAL ONCOLOGY, 2023, 18 (02)
  • [2] Eribulin for advanced breast cancer: Clinical experience in the real world
    Walshaw, Richard C.
    Shaukat, Shazril
    Chan, Kevin
    Armstrong, Anne Caroline
    Howell, Sacha Jon
    Wardley, Andrew M.
    Wilson, Gregory
    Loncaster, Juliet
    Magee, Brian
    Bhatt, Lubna
    Chittalia, Abbas
    Lander, Helen
    Tetlow, Christine
    Misra, Vivek
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Eribulin in Recurrent/Metastatic Breast Cancer (MBC)
    Taha Sethjiwala
    Manikandan Dhanushkodi
    Venkatraman Radhakrishnan
    Jayachandran Perumal Kalaiarasi
    Nikita Mehra
    Archit Joshi
    Arun Kumar Rajan
    Gangothri Selvarajan
    Balasubramanian Ananthi
    Priya Iyer
    Geetha Senguttuvan
    Bharathi Srilatha
    Arvind Krishnamurthy
    Sridevi Velusamy
    Selvaluxmy Ganesarajah
    Trivadi S. Ganesan
    Tenali Gnana Sagar
    Indian Journal of Gynecologic Oncology, 2019, 17
  • [4] Eribulin in Recurrent/Metastatic Breast Cancer (MBC)
    Sethjiwala, Taha
    Dhanushkodi, Manikandan
    Radhakrishnan, Venkatraman
    Kalaiarasi, Jayachandran Perumal
    Mehra, Nikita
    Joshi, Archit
    Rajan, Arun Kumar
    Selvarajan, Gangothri
    Ananthi, Balasubramanian
    Iyer, Priya
    Senguttuvan, Geetha
    Srilatha, Bharathi
    Krishnamurthy, Arvind
    Velusamy, Sridevi
    Ganesarajah, Selvaluxmy
    Ganesan, Trivadi S.
    Sagar, Tenali Gnana
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 17 (03)
  • [5] Systematic evaluation of bevacizumab in recurrent ovarian cancer treatment
    Ding, Shan-Shan
    Li, Li
    Yu, Chun-Xia
    JOURNAL OF BUON, 2014, 19 (04): : 965 - 972
  • [6] Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer
    Feng, Mengya
    Bi, Pingping
    Kang, Yihua
    Yang, Dechun
    Ren, Shengnan
    Lu, Xianping
    Xie, Guojian
    Lei, Hai
    Mo, Dan
    CANCER CELL INTERNATIONAL, 2024, 24 (01)
  • [7] Effect of Bevacizumab and Eribulin for metastatic breast cancer in the real world evaluated using the propensity score matching analysis (PSMA) and inverse probability of treatment weighting analysis (IPTWA)
    Matsui, Koshi
    Earashi, Mitsuharu
    Nagata, Takuya
    Yoshikawa, Akemi
    Fukushima, Wataru
    Nozaki, Zensei
    Tanada, Yasuko
    Oyama, Kaeko
    Shimada, Katsuo
    Kiyohara, Kaoru
    Shimizu, Tetsuro
    Iwata, Keiko
    Yoshida, Toru
    Maeda, Kiichi
    Nakakura, Akiyoshi
    Morita, Satoshi
    Fujii, Tsutomu
    CANCER RESEARCH, 2020, 80 (04)
  • [8] A prospective real-world study of eribulin for HER2-negative recurrent breast cancer patients: final results
    Mukai, Hirofumi
    Inoue, Kenichi
    Takahashi, Masato
    Yamanaka, Takashi
    Egawa, Chiyomi
    Sakata, Yukinori
    Ikezawa, Hiroki
    Matsuoka, Toshiyuki
    Ishii, Mika
    Tsurutani, Junji
    ANNALS OF ONCOLOGY, 2019, 30 : 85 - 85
  • [9] Survival outcomes of metastatic breast cancer who have been treated with bevacizumab and eribulin in the real world. - BEV plus PTX followed by eribulin versus the reverse sequence
    Matsui, K.
    Earashi, M.
    Nagata, T.
    Yoshikawa, A.
    Fukushima, W.
    Nozaki, Z.
    Tanada, Y.
    Oyama, K.
    Shimada, K.
    Kiyohara, K.
    Shimizu, T.
    Iwata, K.
    Yoshida, T.
    Ii, T.
    Maeda, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] Eribulin mesylate for the treatment of breast cancer
    Cigler, Tessa
    Vahdat, Linda T.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (09) : 1587 - 1593
12345